Neuland Laboratories Limited (NEULANDLAB.BO)
INR 14649.65
(-0.98%)
INR 14649.65
(-0.98%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.92 Billion INR | -66.63% |
| 2022 | 3.15 Billion INR | 14.01% |
| 2021 | 2.76 Billion INR | 7.76% |
| 2020 | 2.56 Billion INR | 33.42% |
| 2019 | 1.92 Billion INR | 6.06% |
| 2018 | 1.81 Billion INR | 10.56% |
| 2017 | 1.63 Billion INR | 12.77% |
| 2016 | 1.45 Billion INR | 4.84% |
| 2015 | 1.38 Billion INR | 20.55% |
| 2014 | 1.14 Billion INR | 0.22% |
| 2013 | 1.14 Billion INR | 13.26% |
| 2012 | 1.01 Billion INR | 9.8% |
| 2011 | 922.67 Million INR | 13.37% |
| 2010 | 813.89 Million INR | 73.73% |
| 2009 | 468.47 Million INR | 21.68% |
| 2008 | 384.99 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 300.66 Million INR | -15.51% |
| 2023 Q2 | 1.03 Billion INR | 7.43% |
| 2023 Q1 | 960.54 Million INR | 97.27% |
| 2023 FY | 1.05 Billion INR | -66.63% |
| 2023 Q4 | 355.84 Million INR | -67.09% |
| 2023 Q3 | 1.08 Billion INR | 4.77% |
| 2022 Q3 | 890.68 Million INR | -2.53% |
| 2022 Q2 | 913.78 Million INR | 6.41% |
| 2022 FY | 3.15 Billion INR | 14.01% |
| 2022 Q1 | 858.74 Million INR | 75.23% |
| 2022 Q4 | 486.91 Million INR | -45.33% |
| 2021 FY | 2.76 Billion INR | 7.76% |
| 2021 Q4 | 490.06 Million INR | -36.2% |
| 2021 Q3 | 768.18 Million INR | -4.31% |
| 2021 Q2 | 802.76 Million INR | 14.34% |
| 2021 Q1 | 702.08 Million INR | -2.04% |
| 2020 Q1 | 576.57 Million INR | 19.9% |
| 2020 Q3 | 674.07 Million INR | 8.43% |
| 2020 Q4 | 716.7 Million INR | 6.32% |
| 2020 Q2 | 621.64 Million INR | 7.82% |
| 2020 FY | 2.56 Billion INR | 33.42% |
| 2019 Q3 | 539.02 Million INR | -3.0% |
| 2019 FY | 1.92 Billion INR | 6.06% |
| 2019 Q2 | 555.69 Million INR | 10.9% |
| 2019 Q4 | 480.89 Million INR | -10.79% |
| 2019 Q1 | 501.08 Million INR | 112.37% |
| 2018 FY | 1.81 Billion INR | 10.56% |
| 2018 Q1 | 455.48 Million INR | 0.0% |
| 2018 Q2 | 457.33 Million INR | 0.41% |
| 2018 Q3 | 501.21 Million INR | 9.6% |
| 2018 Q4 | 235.94 Million INR | -52.93% |
| 2017 FY | 1.63 Billion INR | 12.77% |
| 2016 Q3 | 555.41 Million INR | 68.77% |
| 2016 FY | 1.45 Billion INR | 4.84% |
| 2016 Q2 | 329.1 Million INR | -9.45% |
| 2016 Q4 | 364.19 Million INR | -34.43% |
| 2016 Q1 | 363.43 Million INR | 0.0% |
| 2015 FY | 1.38 Billion INR | 20.55% |
| 2014 FY | 1.14 Billion INR | 0.22% |
| 2013 FY | 1.14 Billion INR | 13.26% |
| 2012 FY | 1.01 Billion INR | 9.8% |
| 2011 FY | 922.67 Million INR | 13.37% |
| 2010 FY | 813.89 Million INR | 73.73% |
| 2009 FY | 468.47 Million INR | 21.68% |
| 2008 FY | 384.99 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Ajanta Pharma Limited | 30.46 Billion INR | 90.383% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | -166.586% |
| Sigachi Industries Limited | 579.88 Million INR | -405.227% |
| Bal Pharma Limited | 389.89 Million INR | -651.429% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -37.923% |
| Medico Remedies Limited | 161.84 Million INR | -1710.228% |
| Lasa Supergenerics Limited | 291.17 Million INR | -906.184% |
| Venus Remedies Limited | 1.91 Billion INR | -52.887% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | 4.779% |
| Alpa Laboratories Limited | 156.14 Million INR | -1776.274% |
| Nectar Lifesciences Limited | 625.55 Million INR | -368.347% |
| Shilpa Medicare Limited | 2.18 Billion INR | -34.356% |
| Aarti Drugs Limited | 1.16 Billion INR | -150.946% |
| Lupin Limited | 95.67 Billion INR | 96.938% |
| Aurobindo Pharma Limited | 39.23 Billion INR | 92.533% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 93.214% |
| Windlas Biotech Limited | 1 Billion INR | -191.08% |
| Suven Life Sciences Limited | 109.75 Million INR | -2569.472% |
| Eris Lifesciences Limited | 4.94 Billion INR | 40.729% |
| Valiant Laboratories Limited | 36.28 Million INR | -7973.372% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | 65.193% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | 36.028% |
| Ipca Laboratories Limited | 13.91 Billion INR | 78.945% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -106.433% |
| Achyut Healthcare Limited | 1.6 Million INR | -181984.897% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 98.1% |
| Bajaj HealthCare Limited | 985.34 Million INR | -197.332% |
| RPG Life Sciences Limited | 1.63 Billion INR | -79.135% |
| Mankind Pharma Limited | 23.15 Billion INR | 87.346% |
| Laurus Labs Limited | 3.01 Billion INR | 2.692% |
| Piramal Pharma Limited | 19.91 Billion INR | 85.288% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -210.882% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 86.324% |
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 81.539% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 95.664% |
| Unichem Laboratories Limited | 6.72 Billion INR | 56.441% |
| Sequent Scientific Limited | 2.9 Billion INR | -0.963% |
| Novartis India Limited | 470.1 Million INR | -523.218% |
| Wanbury Limited | 1.16 Billion INR | -152.363% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -108.852% |
| Wockhardt Limited | 6.4 Billion INR | 54.223% |
| Themis Medicare Limited | 782.85 Million INR | -274.239% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -278.809% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 79.731% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 74.832% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 96.944% |
| Divi's Laboratories Limited | 14.17 Billion INR | 79.324% |
| NATCO Pharma Limited | 10.05 Billion INR | 70.871% |
| Gufic Biosciences Limited | 1.07 Billion INR | -171.849% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -166.631% |
| Ind-Swift Limited | 946.56 Million INR | -209.513% |
| Procter & Gamble Health Limited | 2.99 Billion INR | 2.192% |
| FDC Limited | 5.34 Billion INR | 45.223% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -6247.487% |
| Granules India Limited | 7.18 Billion INR | 59.209% |
| Medicamen Biotech Limited | 335.16 Million INR | -774.115% |
| Alkem Laboratories Limited | 32.83 Billion INR | 91.077% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | -12.665% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -17974.031% |
| Brooks Laboratories Limited | 51.18 Million INR | -5624.396% |
| Megasoft Limited | 49.52 Million INR | -5815.333% |
| ZIM Laboratories Limited | 1.01 Billion INR | -189.198% |
| Strides Pharma Science Limited | 9.16 Billion INR | 68.024% |
| Morepen Laboratories Limited | 1.98 Billion INR | -47.412% |
| Hikal Limited | 2.48 Billion INR | -17.834% |
| Indoco Remedies Limited | 4.74 Billion INR | 38.305% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | 4.705% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -610.367% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -333.3% |
| Hester Biosciences Limited | 908.84 Million INR | -222.361% |